MA46625A - Inhibiteurs de lsd1 et leurs utilisations médicales - Google Patents

Inhibiteurs de lsd1 et leurs utilisations médicales

Info

Publication number
MA46625A
MA46625A MA046625A MA46625A MA46625A MA 46625 A MA46625 A MA 46625A MA 046625 A MA046625 A MA 046625A MA 46625 A MA46625 A MA 46625A MA 46625 A MA46625 A MA 46625A
Authority
MA
Morocco
Prior art keywords
medical uses
lsd1 inhibitors
lsd1
inhibitors
medical
Prior art date
Application number
MA046625A
Other languages
English (en)
Other versions
MA46625B1 (fr
Inventor
Francois Brucelle
Victor S Gehling
Avinash Khanna
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Priority claimed from PCT/US2017/058405 external-priority patent/WO2018081343A1/fr
Publication of MA46625A publication Critical patent/MA46625A/fr
Publication of MA46625B1 publication Critical patent/MA46625B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA46625A 2016-10-26 2017-10-26 Inhibiteurs de lsd1 et leurs utilisations médicales MA46625B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413162P 2016-10-26 2016-10-26
PCT/US2017/058405 WO2018081343A1 (fr) 2016-10-26 2017-10-26 Inhibiteurs de lsd1 et leurs utilisations médicales

Publications (2)

Publication Number Publication Date
MA46625A true MA46625A (fr) 2019-09-04
MA46625B1 MA46625B1 (fr) 2023-11-30

Family

ID=65351698

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46625A MA46625B1 (fr) 2016-10-26 2017-10-26 Inhibiteurs de lsd1 et leurs utilisations médicales

Country Status (2)

Country Link
AR (1) AR109887A1 (fr)
MA (1) MA46625B1 (fr)

Also Published As

Publication number Publication date
AR109887A1 (es) 2019-01-30
MA46625B1 (fr) 2023-11-30

Similar Documents

Publication Publication Date Title
EP3870579A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3471727A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3389658A4 (fr) Inhibiteurs de glycosidase et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3600273A4 (fr) Inhibiteurs de cd73 et leurs utilisations
EP3866789A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3344624A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3746075A4 (fr) Inhibiteurs de gcn2 et leurs utilisations
EP3886843A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3523294A4 (fr) Modulateurs de calpain et leurs utilisations thérapeutiques
EP3380100A4 (fr) Inhibiteurs de bromodomaines bivalents et leurs utilisations
IL280863A (en) Autotaxin inhibitors and uses thereof
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3624797A4 (fr) Inhibiteurs de kinase et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
EP3344275A4 (fr) Macrocycles peptidomimétiques et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
EP3341007A4 (fr) Inhibiteurs de malt1 et leurs utilisations
EP3294318A4 (fr) Macrocycles peptidomimétiques et leurs utilisations
EP3341387A4 (fr) Inhibiteurs de sialyltransférase et utilisations de ceux-ci
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
EP3347020A4 (fr) Acétamide thiénotriazoldiazépines et leurs utilisations
EP3362754A4 (fr) Inhibiteurs des protéasomes et leurs utilisations